Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVIVE-HF
NCT03845127Withdrawn
- Sponsor
- BioVentrix, Inc.
- Start
- Jan 2020
- Primary completion
- Dec 2024
- Countries
- 1
01
Overview
Randomised, open-label trial in ischemic cardiomyopathy (ICM) and heart failure (HF) (2 arms), sponsored by BioVentrix, Inc. Primary endpoint: 6 Minute Walking Distance at 6 months. Planned start Jan 2020; status: withdrawn.
02
Conditions
ischemic cardiomyopathy (ICM)heart failure (HF)
Beyond the preview
Go deeper on NCT03845127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03845127.